Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > First financing tranche

<< Previous

Bullboard Posts

Next >>

Comment by Denbrekeron Oct 07, 2020 11:12am

69 Views

Post# 31679909

RE:RE:RE:First financing tranche

Hello, I do a quick check of this stock / news releases / website each 3 months (And no - I am not Lee). Why is the news release on stockwatch saying first and only (?!) tranche? The 3649k units were already closed on 15 July. The objective was 1M-4M CAD => closing at 650k CAD is just dissapointing. Thoughts? Other remarks: - Was the cash already paid on 15 July? Or just committed? - Quid management update in September which refers to a 3.5M financing?

<< Previous

Bullboard Posts

Next >>

98% energy efficiency: How Acceleware's EM Technology is transforming heat solutions